ST Bailing's Tangning Tongluo Tablets Receive Prior Approval for Phase III Clinical Trial from Macau Pharmaceutical Administration Bureau

Regulation
โดย Jiemian·MOCN·Read original
Summary · why it matters

Guizhou Bailing Group Pharmaceutical Co., Ltd., with the stock abbreviation ST Bailing, announced on August 27, 2026, that its wholly-owned grandchild company, Macau Jiliangfang Limited, has received prior approval from the Pharmaceutical Administration Bureau of the Macao Special Administrative Region Government to conduct a Phase III clinical study of its Chinese patent medicine Tangning Tongluo Tablets for the treatment of non-proliferative diabetic retinopathy, specifically the pattern of yin deficiency with internal heat and blood stasis obstructing the eye collaterals. The clinical trial institution is Kiang Wu Hospital. Tangning Tongluo Tablets is a Category 1.1 innovative traditional Chinese medicine developed by the company over more than a decade. The company cautioned that after obtaining the approval, it still needs to complete the clinical trial and the Macau registration review process, and uncertainties remain. The project has not yet generated operating revenue and does not have a material impact on current operating performance.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

澳门济良方有限公司Private▲ Positive
Technologyrelevance

Macau Jiliangfang Limited received prior approval from Macau's Pharmaceutical Administration Bureau to conduct the Phase III clinical study of Tangning Tongluo Tablets.

© 2026 MarketDXNews